NEULANDLABNSENeuland Laboratories Limited· PharmaceuticalsMinimalNeutral
Announced Wed, 13 May · 09:33 IST

Neuland Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

NEULANDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.5%1-day move
₹17100.00
prior close
₹17492.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.1+0.2+0.0-0.9-2.5-3.5-4.7-2.7-2.7-2.5-1.2-0.2+11.0
Up moveDown movePending
AI summary

Neuland Laboratories Limited published its financial results for the quarter and year ended March 31, 2026, in Financial Express and Nava Telangana on May 13, 2026, as required under SEBI Listing Regulations. The results were published in both English and Telugu newspapers. Key figures visible include consolidated total revenue of Rs. 12,249 million, profit after tax of Rs. 4,023 million, and an EBITDA of Rs. 3,799 million for FY 2026. The company highlighted business performance, API/CDMO segment growth, and EBITDA margin improvement of 320 basis points compared to the prior year. The results were signed off by the Company Secretary, Sarada Bhamidipati.

Likely market impact

Routine compliance filing — publication of already-released financial results in newspapers for regulatory completeness. No new price-sensitive information beyond what was already disclosed to exchanges.